Intrinsic danger: Activation of Toll-like receptors in rheumatoid arthritis

Rheumatology

Volumn 51, Issue 1, 2012, Pages 7-23

  Goh, Fui G ^a   Midwood, Kim S ^b  

^a UNIVERSITY OF SHARJAH   (United Arab Emirates)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Damage associated molecular patterns; Rheumatoid arthritis; Therapies; Toll like receptors

Indexed keywords

CHAPERONIN; DILMAPIMOD; DV 1179; IMO 3100; NI 0101; OLIGODEOXYRIBONUCLEOTIDE; OPN 305; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VTX 763;

AUTOIMMUNE DISEASE; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CRYSTAL STRUCTURE; DIMERIZATION; DISEASE COURSE; DOWNSTREAM PROCESSING; DRUG TARGETING; GENE EXPRESSION; HUMAN; IN VIVO STUDY; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STROKE; TISSUE INJURY;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; HUMANS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84855163540     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker257     Document Type: Review

References (225)

1. Klarenbeek NB, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF. Recent advances in the management of rheumatoid arthritis. Br Med J 2010;341:c6942.
2. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008; 26(Suppl. 51):S35-61.
3. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008;223:7-19.
4. Bromley M, Woolley DE. Histopathology of the rheumatoid lesion. Identification of cell types at sites of cartilage erosion. Arthritis Rheum 1984;27:857-63.
5. Shimizu S, Shiozawa S, Shiozawa K, Imura S, Fujita T. Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum 1985;28:25-31.
6. Shiozawa S, Tsumiyama K, Yoshida K, Hashiramoto A. Pathogenesis of joint destruction in rheumatoid arthritis. Arch Immunol Ther Exp 2011;59:89-95.
7. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118: 3537-45.
8. Van Boxel JA, Paget SA. Predominantly T-cell infiltrate in rheumatoid synovial membranes. N Engl J Med 1975;293: 517-20.
9. Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349:1907-15.
10. Chabaud M, Durand JM, Buchs N et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999;42:963-70.
11. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5: 549-53.
12. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
13. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009;5:531-41.
14. Kochi Y, Suzuki A, Yamada R, Yamamoto K. Ethnogenetic heterogeneity of rheumatoid arthritis-implications for pathogenesis. Nat Rev Rheumatol 2010;6:290-5.
15. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004;50: 3085-92.
16. Chujo S, Okamoto S, Sunahara R et al. Cigarette smoke condensate extracts augment collagen-induced arthritis in mice. Int Immunopharmacol 2010;10:1194-9.
17. Okamoto S, Adachi M, Chujo S et al. Etiological role of cigarette smoking in rheumatoid arthritis: Nasal exposure to cigarette smoke condensate extracts augments the development of collagen-induced arthritis in mice. Biochem Biophys Res Commun 2011;404:1088-92.
18. Hashimoto C, Hudson KL, Anderson KV. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988; 52:269-79.
19. Shi Z, Cai Z, Sanchez A et al. A novel Toll-like receptor that recognizes vesicular stomatitis virus. J Biol Chem 2011; 286:4517-24.
20. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008;226: 10-8.
21. Ostuni R, Zanoni I, Granucci F. Deciphering the complexity of Toll-like receptor signaling. Cell Mol Life Sci 2010;67:4109-34.
22. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-7.
23. Akashi-Takamura S, Miyake K. TLR accessory molecules. Curr Opin Immunol 2008;20:420-5.
24. Hasan U, Chaffois C, Gaillard C et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 2005;174:2942-50.
25. Guan Y, Ranoa DR, Jiang S et al. Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. J Immunol 2010;184:5094-103.
26. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004;4:469-78.
27. Ionita MG, Arslan F, de Kleijn DP, Pasterkamp G. Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease. J Innate Immun 2010;2: 307-15.
28. Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 2009; 11:615-28.
29. Foell D, Wittkowski H, Roth J. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat Clin Pract Rheumatol 2007;3:382-90.
30. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010;28:367-88.
31. Marsh BJ, Williams-Karnesky RL, Stenzel-Poore MP. Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 2009;158:1007-20.
32. Funderburg N, Lederman MM, Feng Z et al. Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci USA 2007;104:18631-5.
33. Asea A, Rehli M, Kabingu E et al. Novel signal transduction pathway utilized by extracellular HSP70: role of Toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002;277: 15028-34.
34. Vabulas RM, Braedel S, Hilf N et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem 2002;277:20847-53.
35. Sato M, Sano H, Iwaki D et al. Direct binding of Toll-like receptor 2 to zymosan, and zymosan-induced NF-kappa B activation and TNF-alpha secretion are down-regulated by lung collectin surfactant protein A. J Immunol 2003; 171:417-25.
36. Park JS, Svetkauskaite D, He Q et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279: 7370-7.
37. Park JS, Gamboni-Robertson F, He Q et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006;290:C917-24.
38. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005;115:407-17.
39. Murakami S, Iwaki D, Mitsuzawa H et al. Surfactant protein A inhibits peptidoglycan-induced tumor necrosis factor-alpha secretion in U937 cells and alveolar macrophages by direct interaction with Toll-like receptor 2. J Biol Chem 2002;277:6830-7.
40. Ohya M, Nishitani C, Sano H et al. Human pulmonary surfactant protein D binds the extracellular domains of Toll-like receptors 2 and 4 through the carbohydrate recognition domain by a mechanism different from its binding to phosphatidylinositol and lipopolysaccharide. Biochemistry 2006;45:8657-64.
41. Yang D, Chen Q, Su SB et al. Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med 2008;205:79-90.
42. Satta N, Dunoyer-Geindre S, Reber G et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 2007;109: 1507-14.
43. Zhang P, Cox CJ, Alvarez KM, Cunningham MW. Cutting edge: cardiac myosin activates innate immune responses through TLRs. J Immunol 2009;183:27-31.
44. Park HD, Lee Y, Oh YK et al. Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation. Oncogene 2011;30:201-11.
45. Okamura Y, Watari M, Jerud ES et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001;276:10229-33.
46. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J Immunol 2001;167:2887-94.
47. Midwood K, Sacre S, Piccinini AM et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009;15:774-80.
48. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 2002;168:5989-92.
49. Biragyn A, Ruffini PA, Leifer CA et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002;298:1025-9.
50. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J Immunol 2000;164: 558-61.
51. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 2002;277:15107-12.
52. Roelofs MF, Boelens WC, Joosten LA et al. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J Immunol 2006;176:7021-7.
53. Wheeler DS, Chase MA, Senft AP, Poynter SE, Wong HR, Page K. Extracellular Hsp72, an endogenous DAMP, is released by virally infected airway epithelial cells and activates neutrophils via Toll-like receptor (TLR)-4. Respir Res 2009;10:31.
54. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007;81:28-37.
55. Vogl T, Tenbrock K, Ludwig S et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007;13: 1042-9.
56. Devaney JM, Greene CM, Taggart CC, Carroll TP, O'Neill SJ, McElvaney NG. Neutrophil elastase up-regulates interleukin-8 via Toll-like receptor 4. FEBS Lett 2003;544:129-32.
57. Mulla MJ, Brosens JJ, Chamley LW et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol 2009;62:96-111.
58. Pierangeli SS, Vega-Ostertag ME, Raschi E et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 2007;66:1327-33.
59. Curran CS, Demick KP, Mansfield JM. Lactoferrin activates macrophages via TLR4-dependent and -independent signaling pathways. Cell Immunol 2006;242:23-30.
60. Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI. Resistin competes with lipopolysaccharide for binding to Toll-like receptor 4. J Cell Mol Med 2010;14:1419-31.
61. Hurst J, Prinz N, Lorenz M et al. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology 2009;214:683-91.
62. Doring Y, Hurst J, Lorenz M et al. Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8. Immunobiology 2010;215:230-41.
63. He RL, Zhou J, Hanson CZ, Chen J, Cheng N, Ye RD. Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 2009;113: 429-37.
64. Cheng N, He R, Tian J, Ye PP, Ye RD. Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol 2008;181:22-6.
65. West XZ, Malinin NL, Merkulova AA et al. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 2010;467:972-6.
66. Sandri S, Rodriguez D, Gomes E, Monteiro HP, Russo M, Campa A. Is serum amyloid A an endogenous TLR4 agonist? J Leukoc Biol 2008;83:1174-80.
67. Hiratsuka S, Watanabe A, Sakurai Y et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 2008;10: 1349-55.
68. Xu XH, Shah PK, Faure E et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001;104:3103-8.
69. Bae YS, Lee JH, Choi SH et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: Toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res 2009;104:210-8, 21p following 8.
70. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003;278:1561-8.
71. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-25.
72. Schaeffler A, Gross P, Buettner R et al. Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling with innate immunity. Immunology 2009;126:233-45.
73. Schaefer L, Babelova A, Kiss E et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005;115:2223-33.
74. Kim S, Takahashi H, Lin WW et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009;457:102-6.
75. Termeer C, Benedix F, Sleeman J et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med 2002;195:99-111.
76. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002;168:5233-9.
77. Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005;52:2936-46.
78. Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol 2005;174:5016-23.
79. Kariko K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004;279:12542-50.
80. Vollmer J, Tluk S, Schmitz C et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005;202:1575-85.
81. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7.
82. O'Neill LA, Bowie AG. The family of five: TIR-domaincontaining adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007;7:353-64.
83. Heguy A, Baldari CT, Macchia G, Telford JL, Melli M. Amino acids conserved in interleukin-1 receptors (IL-1Rs) and the Drosophila Toll protein are essential for IL-1R signal transduction. J Biol Chem 1992;267:2605-9.
84. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998; 95:588-93.
85. Lasker MV, Nair SK. Intracellular TLR signaling: a structural perspective on human disease. J Immunol 2006; 177:11-6.
86. Coll RC, O'Neill LA. New insights into the regulation of signalling by Toll-like receptors and nod-like receptors. J Innate Immun 2010;2:406-21.
87. Yamamoto M, Takeda K, Akira S. TIR domain-containing adaptors define the specificity of TLR signaling. Mol Immunol 2004;40:861-8.
88. Yamamoto M, Sato S, Hemmi H et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 2003;4:1144-50.
89. West AP, Koblansky AA, Ghosh S. Recognition and signaling by Toll-like receptors. Annu Rev Cell Dev Biol 2006;22:409-37.
90. Jin MS, Kim SE, Heo JY et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007;130:1071-82.
91. Kang JY, Nan X, Jin MS et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 2009;31:873-84.
92. Kim HM, Park BS, Kim JI et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007;130:906-17.
93. Liu L, Botos I, Wang Y et al. Structural basis of Toll-like receptor 3 signaling with double-stranded RNA. Science 2008;320:379-81.
94. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009;458:1191-5.
95. Tanabe M, Nimigean CM, Iverson TM. Structural basis for solute transport, nucleotide regulation, and immunological recognition of Neisseria meningitidis PorB. Proc Natl Acad Sci USA 2010;107:6811-6.
96. Codolo G, Papinutto E, Polenghi A, D'Elios MM, Zanotti G, de Bernard M. Structure and immunomodulatory property relationship in NapA of Borrelia burgdorferi. Biochim Biophys Acta 2010;1804:2191-7.
97. Yu S, Lee NY, Park SJ, Rhee S. Crystal structure of Toll-like receptor 2-activating lipoprotein IIpA from Vibrio vulnificus. Proteins 2011;79:1020-5.
98. Drage MG, Tsai HC, Pecora ND et al. Mycobacterium tuberculosis lipoprotein LprG (Rv1411c) binds triacylated glycolipid agonists of Toll-like receptor 2. Nat Struct Mol Biol 2010;17:1088-95.
99. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010; doi:10.1155/2010/672395.
100. Hodgkinson CP, Patel K, Ye S. Functional Toll-like receptor 4 mutations modulate the response to fibrinogen. Thromb Haemost 2008;100:301-7.
101. Babelova A, Moreth K, Tsalastra-Greul W et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via Toll-like and P2X receptors. J Biol Chem 2009;284: 24035-48.
102. Kol A, Lichtman AH, Finberg RW, Libby P, Kurt-Jones EA. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol 2000;164:13-7.
103. Taylor KR, Yamasaki K, Radek KA et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem 2007;282:18265-75.
104. Stewart CR, Stuart LM, Wilkinson K et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010;11:155-61.
105. Ganguly D, Chamilos G, Lande R et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009;206:1983-94.
106. Lau CM, Broughton C, Tabor AS et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005;202:1171-7.
107. Lande R, Gregorio J, Facchinetti V et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007;449:564-9.
108. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity 2003;19: 837-47.
109. Urbonaviciute V, Furnrohr BG, Meister S et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008;205:3007-18.
110. Tian J, Avalos AM, Mao SY et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8:487-96.
111. Silva E, Arcaroli J, He Q et al. HMGB1 and LPS induce distinct patterns of gene expression and activation in neutrophils from patients with sepsis-induced acute lung injury. Intensive Care Med 2007;33:1829-39.
112. Youn JH, Oh YJ, Kim ES, Choi JE, Shin JS. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol 2008;180: 5067-74.
113. Hreggvidsdottir HS, Ostberg T, Wahamaa H et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol 2009;86:655-62.
114. Warger T, Hilf N, Rechtsteiner G et al. Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem 2006;281:22545-53.
115. Ospelt C, Brentano F, Rengel Y et al. Overexpression of Toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: Toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum 2008;58:3684-92.
116. Seibl R, Birchler T, Loeliger S et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003;162:1221-7.
117. Huang Q, Ma Y, Adebayo A, Pope RM. Increased macrophage activation mediated through Toll-likereceptors in rheumatoid arthritis. Arthritis Rheum 2007; 56:2192-201.
118. Kim KW, Cho ML, Lee SH et al. Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation. Immunol Lett 2007;110:54-64.
119. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005;52:2656-65.
120. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S et al. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005;52:2313-22.
121. Kim KW, Cho ML, Oh HJ et al. TLR-3 enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis. Immunol Lett 2009; 124:9-17.
122. Sacre SM, Andreakos E, Kiriakidis S et al. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol 2007;170:518-25.
123. Wu CY, Chi PL, Hsieh HL, Luo SF, Yang CM. TLR4-dependent induction of vascular adhesion molecule-1 in rheumatoid arthritis synovial fibroblasts: roles of cytosolic phospholipase A(2)alpha/ cyclooxygenase-2. J Cell Physiol 2010;223:480-91.
124. Sacre SM, Lo A, Gregory B et al. Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures. J Immunol 2008;181:8002-9.
125. Tamaki Y, Takakubo Y, Hirayama T et al. Expression of Toll-like receptors and their signaling pathways in rheumatoid synovitis. J Rheumatol 2011;38:810-20.
126. Deng GM, Nilsson IM, Verdrengh M, Collins LV, Tarkowski A. Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med 1999;5: 702-5.
127. Cromartie WJ, Craddock JG, Schwab JH, Anderle SK, Yang CH. Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med 1977;146: 1585-602.
128. Williams RO. Models of rheumatoid arthritis. Ernst Schering Res Found Workshop 2005;50:89-117.
129. Frasnelli ME, Tarussio D, Chobaz-Peclat V, Busso N, So A. TLR2 modulates inflammation in zymosan-induced arthritis in mice. Arthritis Res Ther 2005;7:R370-9.
130. Lee EK, Kang SM, Paik DJ, Kim JM, Youn J. Essential roles of Toll-like receptor-4 signaling in arthritis induced by type II collagen antibody and LPS. Int Immunol 2005; 17:325-33.
131. Joosten LA, Koenders MI, Smeets RL et al. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J Immunol 2003;171:6145-53.
132. Choe JY, Crain B, Wu SR, Corr M. Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by Toll-like receptor 4 signaling. J Exp Med 2003;197:537-42.
133. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003;100:5986-90.
134. Koenders MI, Devesa I, Marijnissen RJ et al. Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum 2008;58: 3461-70.
135. Abdollahi-Roodsaz S, Joosten LA, Koenders MI et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 2008;118:205-16.
136. Hayashi T, Gray CS, Chan M et al. Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc Natl Acad Sci USA 2009;106: 2764-9.
137. Meng L, Zhu W, Jiang C et al. Toll-like receptor 3 upregulation in macrophages participates in the initiation and maintenance of pristane-induced arthritis in rats. Arthritis Res Ther 2010;12:R103.
138. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004;303:1526-9.
139. Lundberg AM, Drexler SK, Monaco C et al. Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. Blood 2007;110:3245-52.
140. Goh FG, Thomson SJ, Krausgruber T, Lanfrancotti A, Copley RR, Udalova IA. Beyond the enhanceosome: cluster of novel kappaB sites downstream of the human IFN-beta gene is essential for lipopolysaccharide-induced gene activation. Blood 2010;116:5580-8.
141. Schmidt M, Raghavan B, Muller V et al. Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol 2010;11:814-9.
142. Stahl HD, Hubner B, Seidl B et al. Detection of multiple viral DNA species in synovial tissue and fluid of patients with early arthritis. Ann Rheum Dis 2000;59:342-6.
143. van der Heijden IM, Wilbrink B, Tchetverikov I et al. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum 2000;43:593-8.
144. Schumacher HR Jr, Arayssi T, Crane M et al. Chlamydia trachomatis nucleic acids can be found in the synovium of some asymptomatic subjects. Arthritis Rheum 1999; 42:1281-4.
145. Gondokaryono SP, Ushio H, Niyonsaba F et al. The extra domain A of fibronectin stimulates murine mast cells via Toll-like receptor 4. J Leukoc Biol 2007;82: 657-65.
146. Sokolove J, Zhao X, Chandra PE, Robinson WH. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum 2011;63:53-62.
147. Lipsky PE. Are new agents needed to treat RA? Nat Rev Rheumatol 2009;5:521-2.
148. Hedayat M, Takeda K, Rezaei N. Prophylactic and therapeutic implications of Toll-like receptor ligands. Med Res Rev 2010; doi:10.1002/med.20214.
149. Basith S, Manavalan B, Lee G, Kim SG, Choi S. Toll-like receptor modulators: a patent review (2006 - 2010). Expert Opin Ther Pat 2011;21:927-44.
150. Makkouk A, Abdelnoor AM. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents. Immunopharmacol Immunotoxicol 2009;31:331-8.
151. Clanchy FI, Sacre SM. Modulation of toll-like receptor function has therapeutic potential in autoimmune disease. Expert Opin Biol Ther 2010;10:1703-16.
152. Midwood KS, Piccinini AM, Sacre S. Targeting Toll-like receptors in autoimmunity. Curr Drug Targets 2009;10: 1139-55.
153. Cbio Ltd. http://www.cbio.com.au (last accessed April 2011).
154. NovImmune. http://www.novimmune.com (last accessed April 2011).
155. Opsona Therapeutics. http://www.opsona.com (last accessed April 2011).
156. Idera Pharmaceutical. http://www.iderapharma.com (last accessed April 2011).
157. Dynavax. http://www.dynavax.com (last accessed April 2011).
158. VentiRx Pharmaceuticals. http://www.ventirx.com (last accessed April 2011).
159. GlaxoSmithKline. http://www.gsk.com (last accessed April 2011).
160. Abdollahi-Roodsaz S, Joosten LA, Roelofs MF et al. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 2007;56:2957-67.
161. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004;173:145-50.
162. Drexler SK, Kong P, Inglis J et al. SIGIRR/TIR-8 is an inhibitor of Toll-like receptor signaling in primary human cells and regulates inflammation in models of rheumatoid arthritis. Arthritis Rheum 2010;62:2249-61.
163. Iwami KI, Matsuguchi T, Masuda A, Kikuchi T, Musikacharoen T, Yoshikai Y. Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol 2000;165: 6682-6.
164. Schnabl B, Brandl K, Fink M et al. A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. Biochem Biophys Res Commun 2008;375:210-4.
165. Zunt SL, Burton LV, Goldblatt LI, Dobbins EE, Srinivasan M. Soluble forms of Toll-like receptor 4 are present in human saliva and modulate tumour necrosis factor-alpha secretion by macrophage-like cells. Clin Exp Immunol 2009;156:285-93.
166. Kopp A, Bala M, Buechler C et al. C1q/TNF-related protein-3 represents a novel and endogenous lipopolysaccharide antagonist of the adipose tissue. Endocrinology 2010;151:5267-78.
167. Johnson BJ, Le TT, Dobbin CA et al. Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. J Biol Chem 2005;280:4037-47.
168. Datla P, Kalluri MD, Basha K et al. 9,10-dihydro-2,5-dimethoxyphenanthrene-1,7-diol, from Eulophia ochreata, inhibits inflammatory signalling mediated by Toll-like receptors. Br J Pharmacol 2010;160: 1158-70.
169. Kalluri MD, Datla P, Bellary A et al. Novel synthetic gluco-disaccharide RSCL-0409-a lipopolysaccharide-induced Toll-like receptor-mediated signalling antagonist. FEBS J 2010;277:1639-52.
170. Duan GJ, Zhu J, Wan JY et al. A synthetic MD-2 mimetic peptide attenuates lipopolysaccharide-induced inflammatory responses in vivo and in vitro. Int Immunopharmacol 2010;10:1091-100.
171. Piazza M, Calabrese V, Baruffa C, Gioannini T, Weiss J, Peri F. The cationic amphiphile 3,4-bis(tetradecyloxy) benzylamine inhibits LPS signaling by competing with endotoxin for CD14 binding. Biochem Pharmacol 2010; 80:2050-6.
172. Park SJ, Kang SH, Kang YK et al. Inhibition of homodimerization of Toll-like receptor 4 by 4-oxo-4-(2-oxooxazolidin-3-yl)-but-2-enoic acid ethyl ester. Int Immunopharmacol 2011;11:19-22.
173. Youn HS, Kim YS, Park ZY et al. Sulforaphane suppresses oligomerization of TLR4 in a thiol-dependent manner. J Immunol 2010;184:411-9.
174. LeBouder E, Rey-Nores JE, Rushmere NK et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 2003;171:6680-9.
175. Dulay AT, Buhimschi CS, Zhao G et al. Soluble TLR2 is present in human amniotic fluid and modulates the intraamniotic inflammatory response to infection. J Immunol 2009;182:7244-53.
176. Raby AC, Le Bouder E, Colmont C et al. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. J Immunol 2009;183:506-17.
177. Nic An Ultaigh S, Saber TP, McCormick J et al. Blockade of Toll-like receptor 2 prevents spontaneous cytokine release from rheumatoid arthritis ex vivo synovial explant cultures. Arthritis Res Ther 2011;13:R33.
178. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: From Malaria to Autoimmunity. Clin Rev Allergy Immunol 2011; doi:10.1007/s12016-010-8243-x.
179. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines. J Immunol 2011;186:4794-804.
180. Sacre S, Medghalchi M, Gregory B, Brennan F, Williams R. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit Toll-like receptors. Arthritis Rheum 2010;62:683-93.
181. Ranjith-Kumar CT, Duffy KE, Jordan JL et al. Single-stranded oligonucleotides can inhibit cytokine production induced by human Toll-like receptor 3. Mol Cell Biol 2008;28:4507-19.
182. Barrat FJ, Meeker T, Gregorio J et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131-9.
183. Lenert PS. Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm 2010;2010: 986596.
184. Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligonucleotides protect against collagen-induced arthritis in mice. Arthritis Rheum 2004;50:1686-9.
185. Zeuner RA, Ishii KJ, Lizak MJ et al. Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis Rheum 2002;46:2219-24.
186. Hammaker D, Firestein GS. "Go upstream, young man": lessons learned from the p38 saga. Ann Rheum Dis 2010;69(Suppl. 1):i77-82.
187. Alten RE, Zerbini C, Jeka S et al. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis 2010;69:364-7.
188. Cohen SB, Cheng TT, Chindalore V et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:335-44.
189. Mourey RJ, Burnette BL, Brustkern SJ et al. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J Pharmacol Exp Ther 2010;333:797-807.
190. Kang JS, Kim HM, Choi IY et al. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway. J Pharmacol Exp Ther 2010;334:657-64.
191. Hammaker D, Sweeney S, Firestein GS. Signal transduction networks in rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl. 2):ii86-9.
192. Schopf L, Savinainen A, Anderson K et al. IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. Arthritis Rheum 2006;54:3163-73.
193. Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther 2005;7:R1348-59.
194. Okamoto H, Yoshio T, Kaneko H, Yamanaka H. Inhibition of NF-kappaB signaling by fasudil as a potential therapeutic strategy for rheumatoid arthritis. Arthritis Rheum 2010;62:82-92.
195. Iyer S, Kontoyiannis D, Chevrier D et al. Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J Biol Chem 2000;275:17051-7.
196. DeVry CG, Valdez M, Gao L et al. RDP58, a novel immunomodulatory peptide, ameliorates clinical signs of disease in the Lewis rat model of acute experimental autoimmune encephalomyelitis. J Neuroimmunol 2004; 152:33-43.
197. Liu W, Deyoung BR, Chen X, Evanoff DP, Luo Y. RDP58 inhibits T cell-mediated bladder inflammation in an autoimmune cystitis model. J Autoimmun 2008;30: 257-65.
198. genzyme. http://www.genzyme.com (last accessed April 2011).
199. Loiarro M, Capolunghi F, Fanto N et al. Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol 2007;82:801-10.
200. Capolunghi F, Rosado MM, Cascioli S et al. Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. Rheumatology 2010;49:2281-9.
201. Kokkola R, Li J, Sundberg E et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003;48: 2052-8.
202. Rice JW, Veal JM, Fadden RP et al. Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum 2008;58: 3765-75.
203. Pisetsky DS, Erlandsson-Harris H, Andersson U. High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 2008;10:209.
204. Andersson U, Harris HE. The role of HMGB1 in the pathogenesis of rheumatic disease. Biochim Biophys Acta 2010;1799:141-8.
205. Wang H, Liao H, Ochani M et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004;10:1216-21.
206. Tang D, Kang R, Xiao W et al. Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am J Respir Cell Mol Biol 2009;41:651-60.
207. Chen G, Li J, Qiang X et al. Suppression of HMGB1 release by stearoyl lysophosphatidylcholine: an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res 2005;46:623-7.
208. Johnson GB, Brunn GJ, Platt JL. Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J Immunol 2004;172:20-4.
209. Kakimoto K, Matsukawa A, Yoshinaga M, Nakamura H. Suppressive effect of a neutrophil elastase inhibitor on the development of collagen-induced arthritis. Cell Immunol 1995;165:26-32.
210. Grimstein C, Choi YK, Wasserfall CH et al. Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model. J Transl Med 2011;9:21.
211. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010;466:835-40.
212. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008;455:64-71.
213. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009;32: 189-94.
214. O'Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 2011;11:163-75.
215. Sheedy FJ, Palsson-McDermott E, Hennessy EJ et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010;11:141-7.
216. Stanczyk J, Pedrioli DM, Brentano F et al. Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 2008; 58:1001-9.
217. Li J, Wan Y, Guo Q et al. Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther 2010;12:R81.
218. Stanczyk J, Ospelt C, Karouzakis E et al. Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum 2011;63:373-81.
219. Govindaraj RG, Manavalan B, Lee G, Choi S. Molecular modeling-based evaluation of hTLR10 and identification of potential ligands in Toll-like receptor signaling. PLoS One 2010;5:e12713.
220. Hirata N, Yanagawa Y, Ebihara T et al. Selective synergy in anti-inflammatory cytokine production upon cooperated signaling via TLR4 and TLR2 in murine conventional dendritic cells. Mol Immunol 2008;45: 2734-42.
221. Vanhoutte F, Paget C, Breuilh L et al. Toll-like receptor (TLR)2 and TLR3 synergy and cross-inhibition in murine myeloid dendritic cells. Immunol Lett 2008;116:86-94.
222. Rallabhandi P, Nhu QM, Toshchakov VY et al. Analysis of proteinase-activated receptor 2 and TLR4 signal transduction: a novel paradigm for receptor cooperativity. J Biol Chem 2008;283:24314-25.
223. Kanke T, Takizawa T, Kabeya M, Kawabata A. Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2 as a potential therapeutic target. J Pharmacol Sci 2005;97:38-42.
224. Goon Goh F, Sloss CM, Cunningham MR, Nilsson M, Cadalbert L, Plevin R. G-protein-dependent andindependent pathways regulate proteinase-activated receptor-2 mediated p65 NFkappaB serine 536 phosphorylation in human keratinocytes. Cell Signal 2008;20:1267-74.
225. Nhu QM, Shirey K, Teijaro JR et al. Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal Immunol 2010;3:29-39.